EUVIMEDEUVIMED entdecken
FallberichtSystematische ÜbersichtOpen Access

Dupilumab for the treatment of eczema molluscatum: A pediatric case report and systematic literature review

Patrick E Obermeier iD, Uda Puzich, Annika Brinkmann, Livia Schrick, Alexandra Mühlendyck

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026

DOI: 10.1111/ddg.70176 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2026. Verfasst von Patrick E Obermeier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Vaccine Safety Initiative, Berlin, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic, Eczema, Molluscum Contagiosum. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) may be complicated by disseminated molluscum contagiosum virus (MOCV) infection, known as eczema molluscatum (EM), particularly in children. Topical treatments are not always effective, and although modern systemic immunomodulatory therapies for AD, including use in early childhood, are available, their impact on co‐occurring MCV infection is not well documented. We present a 4‐year‐old child with severe EM that was refractory to conventional topical therapy. She was treated with dupilumab (300 mg subcutaneously every four weeks), which led to a rapid resolution of symptoms and clinical clearance of MOCV‐1 infection without adverse events. To contextualize our findings, we performed a systematic literature review, including PubMed, ScienceDirect, Scopus, and Google Scholar, to identify published case descriptions of dupilumab use with co‐occurring MOCV infection (PROSPERO ID CRD420251106639). We identified a total of six publications reporting on nine adult patients (mean age: 40 years, range: 21–58 years, 8/9 male). In five of these patients, EM temporarily flared up before resolution. The present report is the first of a child. Our findings, along with existing reports, suggest that dupilumab may be a safe and effective treatment option for AD patients with MOCV infection. Prospective evaluation using standardized outcome measures is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedDermatitis, AtopicEczemaMolluscum ContagiosumChild, PreschoolFemaleHumansInjections, SubcutaneousTreatment Outcome

Stichwörter der Autor:innen

Atopic dermatitisIL‐13IL‐4case reportdupilumabmolluscum contagiosumpediatric dermatologyskin infection

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Department of Infectious Diseases, Vaccine Safety Initiative, Berlin, Germany.
  • Hautarztpraxis am Rüdesheimer Platz, Berlin, Germany.
  • Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses & German Consultant Laboratory for Poxviruses, Robert Koch-Institute, Berlin, Germany.

ORCID-Profile: Patrick E Obermeier

Zitieren

APA

Obermeier, P. E., Puzich, U., Brinkmann, A., Schrick, L., & Mühlendyck, A. (2026). Dupilumab for the treatment of eczema molluscatum: A pediatric case report and systematic literature review. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.70176

Vancouver

Obermeier PE, Puzich U, Brinkmann A, Schrick L, Mühlendyck A. Dupilumab for the treatment of eczema molluscatum: A pediatric case report and systematic literature review. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.70176

BibTeX
@article{Obermeier2026,
  author = {Obermeier, Patrick E and Puzich, Uda and Brinkmann, Annika and Schrick, Livia and Mühlendyck, Alexandra},
  title = {Dupilumab for the treatment of eczema molluscatum: A pediatric case report and systematic literature review},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2026},
  doi = {10.1111/ddg.70176}
}
Kostenlos starten →